ATC Group: V09AX04 Flutemetamol (18F)

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of V09AX04 in the ATC hierarchy

Level Code Title
1 V Various
2 V09 Diagnostic radiopharmaceuticals
3 V09A Central nervous system
4 V09AX Other central nervous system diagnostic radiopharmaceuticals
5 V09AX04

Active ingredients in V09AX04

Active Ingredient Description
Flutemetamol ¹⁸F

Flutemetamol ¹⁸F binds to β-amyloid neuritic plaques in the brain. It is a radiopharmaceutical medicinal product indicated for Positron Emission Tomography (PET) imaging of β-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. VIZAMYL should be used in conjunction with a clinical evaluation.

Related product monographs

Title Information Source Document Type  
VIZAMYL Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicines in this ATC group

United States (US)

Austria (AT)

Estonia (EE)

France (FR)

Ireland (IE)

Japan (JP)

Lithuania (LT)

Poland (PL)

Singapore (SG)

Spain (ES)

Turkey (TR)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.